CRISPR-based genome editing is emerging as a frontrunner in gene therapy research. Conventionally, viral vectors, and more recently, nanoparticles have been the choice of delivery platforms in vivo. Watch this webinar to learn how protein-RNA engineering and pre-formed CRISPR complexes are now being harnessed for targeted in vivo delivery in gene therapy research.

Watch this webinar to learn from the presenters:

Kevin Holden, Ph.D., Head of Science, Synthego, talks about Integrating CRISPR genome engineering workflows into novel automation platforms. How Synthego enables the possibility of in vivo CRISPR therapeutics through RNA synthesis capabilities.

Max Sellman, Product Manager, Aldevron, talks about the custom GMP ribonucleoprotein production platforms at Aldevron.

Ross Wilson, Ph.D., Assistant Adjunct Professor, University of California, Berkeley, talks about performing molecular engineering, giving CRISPR enzymes the properties necessary for safe, efficient, and accessible delivery in a clinical setting. These efforts will enable in vivo delivery of CRISPR enzymes, including hard-to-deliver tools such as base editors and prime editors.